Online datafile_v1.xlsx (449.14 kB)
BiOCURA-metabolomic profiles and clinical parameters
Patients were selected from the observational
BiOCURA study in which patients were enrolled between 2009
and 2015. Serum samples from selected subjects were measured
on three targeted LC-MS platforms, covering a broad
spectrum of pre-defined metabolites. The lipid platform targets low abundance
lipid species, including free fatty acids (FAs) and phospholipid derivates,
such as lysophosphatidylcholines (LPCs) and lysophosphatidylethanolamines
(LPEs); the oxylipins platform covers oxygenated metabolites derived from
polyunsaturated fatty acids through enzymatic and non-enzymatic oxidation
processes; the amine platform targets amino acids and biogenic amines.
Demographic, clinical, and laboratory parameters of
patients at baseline were obtained, including age, gender, menopausal status, body
mass index (BMI), disease duration, any previously used bDMARD (biological
naivety), currently used csDMARDs and non-anti-rheumatic drugs, 28 tender joint
count (TJC), 28 swollen joint count (SJC), a 100mm visual analogue scale on
general health (VAS-GH), erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), rheumatoid factor (RF), and anti-citrullinated protein antibody
(ACPA). Disease activity was assessed at baseline and at follow-up visits,
using DAS28 (disease activity score based on a 28-joint count) to evaluate therapeutic responses.
